Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab in Adults With Advanced Solid Tumors
The purpose of this study is to assess the safety and pharmacokinetics of boserolimab (MK-5890) when administered alone and in combination with pembrolizumab (MK-3475) in adults with advanced solid tumors. The